Your gateway to a free society
Article

Subsidizing Higher Education Is Not Creating Widespread External Benefits

Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Feb 23, 2026 / Dave DeCamp
After Four Years of War, Zelensky Insists Victory Requires Ukraine Reclaiming All Territory Captured by Russia
Tuesday marks four years since Russia first launched its invasion of Ukraine, and, despite President Trump promising to end the war quickly, there’s no end in sight to the conflict as Russian and Ukrainian leadership haven’t budged on their core demands for a peace deal. Ukrainian President Volodymyr Zelensky reaffirmed in an interview with the […]
Read more
Feb 22, 2026 / Tyler Durden
"We'll Be Monitoring This Case": US State Dept Condemns Far-Left Activists Killing Of French Conservative
"We'll Be Monitoring This Case": US State Dept Condemns Far-Left Activists Killing Of French Conservative Authored by Thomas Brooke via Remix News, The U.S. government has weighed in on the killing of French conservative student Quentin Deranque by far-left militant activists, warning that “violent radical leftism is on the rise,” and demanding that those responsible be brought to justice. In a statement posted on X, the U.S. Department of State Bureau of Counterterrorism said, “Reports, corroborated by the French Minister of the Interior, that Quentin Deranque was killed by left-wing militants, should...
Read more
Feb 23, 2026 / Tyler Durden
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival
"Worst-Case Scenario": Novo Nordisk Plunges After Next-Gen Obesity Drug Falls Short Of Lilly Rival Shares of Novo Nordisk A/S plummeted again on Monday after the company reported trial results showing its next-generation obesity shot, CagriSema, delivered 20.2% weight loss at 84 weeks, compared to 23.6% for Eli Lilly & Co.’s tirzepatide (Zepbound). Bloomberg Intelligence analyst Michael Shah explained, "This outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1/Amylin drug." Shares of Novo in Copenhagen plunged as much as 16.5%, breaking below a support level...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.